PolarityTE Inc. (PTE), a company focused on regenerative tissue products and biomaterials, said on Tuesday that it has received FDA clearance to commence the first of two planned phase III trials of SkinTE to treat chronic cutaneous ulcers.
SkinTE is a human cellular and tissue-based product derived from a patient's own skin.
The first planned phase III trial, dubbed COVER DFUs, is designed to enroll up to 100 patients at up to 20 sites in the U.S. which will compare treatment with SkinTE plus the standard-of-care to the standard-of-care alone. Enrollment in this trial is expected to begin later this quarter or in early second quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.